These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 15215115

  • 21. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
    File TM, Jacobs MR, Poole MD, Wynne B, 546, 547, 548, 549, 550, 551, 556, 557 and 592 Clinical Study Groups.
    Int J Antimicrob Agents; 2002 Oct; 20(4):235-47. PubMed ID: 12385678
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of simulated cefditoren versus amoxicillin-clavulanate free concentrations in countering intrastrain ftsI gene diffusion in Haemophilus influenzae.
    González N, Aguilar L, Sevillano D, Giménez MJ, Alou L, Cafini F, Torrico M, López AM, Coronel P, Prieto J.
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2788-94. PubMed ID: 21464255
    [Abstract] [Full Text] [Related]

  • 23. Treatment of acute bacterial rhinosinusitis caused by antimicrobial-resistant Streptococcus pneumoniae.
    Anon JB.
    Am J Med; 2004 Aug 02; 117 Suppl 3A():23S-28S. PubMed ID: 15360094
    [Abstract] [Full Text] [Related]

  • 24. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
    Petitpretz P, Chidiac C, Soriano F, Garau J, Stevenson K, Rouffiac E, 556 Clinical Study Group.
    Int J Antimicrob Agents; 2002 Aug 02; 20(2):119-29. PubMed ID: 12297361
    [Abstract] [Full Text] [Related]

  • 25. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media.
    Fenoll A, Aguilar L, Robledo O, Giménez MJ, Tarragó D, Granizo JJ, Gimeno M, Coronel P.
    J Antimicrob Chemother; 2007 Aug 02; 60(2):323-7. PubMed ID: 17562681
    [Abstract] [Full Text] [Related]

  • 26. Effect of cloned inhibitor-resistant TEM beta-lactamases on the susceptibility of Haemophilus influenzae to amoxicillin/clavulanate.
    Tristram SG, Burdach JG.
    J Antimicrob Chemother; 2007 Nov 02; 60(5):1151-4. PubMed ID: 17827143
    [Abstract] [Full Text] [Related]

  • 27. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
    Harrison CJ, Woods C, Stout G, Martin B, Selvarangan R.
    J Antimicrob Chemother; 2009 Mar 02; 63(3):511-9. PubMed ID: 19174454
    [Abstract] [Full Text] [Related]

  • 28. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M, Browne FA, Jacobs MR, Appelbaum PC.
    Clin Ther; 2003 Jan 02; 25(1):169-77. PubMed ID: 12637118
    [Abstract] [Full Text] [Related]

  • 29. Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles.
    Dagan R.
    Int J Infect Dis; 2003 Mar 02; 7 Suppl 1():S21-6. PubMed ID: 12839704
    [Abstract] [Full Text] [Related]

  • 30. In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin.
    Clark C, Bozdogan B, Peric M, Dewasse B, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2002 Sep 02; 46(9):2956-62. PubMed ID: 12183253
    [Abstract] [Full Text] [Related]

  • 31. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
    Bogdanovich T, Clark C, Ednie L, Lin G, Smith K, Shapiro S, Appelbaum PC.
    Antimicrob Agents Chemother; 2006 Jun 02; 50(6):2050-7. PubMed ID: 16723565
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
    Sethi S, Breton J, Wynne B.
    Antimicrob Agents Chemother; 2005 Jan 02; 49(1):153-60. PubMed ID: 15616290
    [Abstract] [Full Text] [Related]

  • 33. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.
    Thornsberry C, Ogilvie P, Kahn J, Mauriz Y.
    Diagn Microbiol Infect Dis; 1997 Dec 02; 29(4):249-57. PubMed ID: 9458982
    [Abstract] [Full Text] [Related]

  • 34. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model].
    Gómez-Lus ML, García Y, Valero E, Amores R, Fuentes F.
    Rev Esp Quimioter; 2000 Sep 02; 13(3):306-13. PubMed ID: 11086282
    [Abstract] [Full Text] [Related]

  • 35. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
    Seral C, Suárez L, Rubio-Calvo C, Gómez-Lus R, Gimeno M, Coronel P, Durán E, Becerril R, Oca M, Castillo FJ.
    Diagn Microbiol Infect Dis; 2008 Oct 02; 62(2):210-5. PubMed ID: 18715733
    [Abstract] [Full Text] [Related]

  • 36. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia.
    Torumkuney D, Mayanskiy N, Edelstein M, Sidorenko S, Kozhevin R, Morrissey I.
    J Antimicrob Chemother; 2018 Apr 01; 73(suppl_5):v14-v21. PubMed ID: 29659881
    [Abstract] [Full Text] [Related]

  • 37. Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.
    Easton J, Noble S, Perry CM.
    Drugs; 2003 Apr 01; 63(3):311-40. PubMed ID: 12534334
    [Abstract] [Full Text] [Related]

  • 38. Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.
    Sevillano D, Calvo A, Giménez MJ, Alou L, Aguilar L, Valero E, Carcas A, Prieto J.
    J Antimicrob Chemother; 2004 Dec 01; 54(6):1148-51. PubMed ID: 15489246
    [Abstract] [Full Text] [Related]

  • 39. Contribution of beta-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in beta-lactamase-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae.
    Matic V, Bozdogan B, Jacobs MR, Ubukata K, Appelbaum PC.
    J Antimicrob Chemother; 2003 Dec 01; 52(6):1018-21. PubMed ID: 14585854
    [Abstract] [Full Text] [Related]

  • 40. In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
    Amores R, Alou L, Giménez MJ, Sevillano D, Gómez-Lus ML, Aguilar L, Prieto J.
    Int J Antimicrob Agents; 2004 Jul 01; 24(1):79-82. PubMed ID: 15225866
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.